pipeline-prospector-insert
X

Find Oncology Drugs in Phase I Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Napabucasin

            Therapeutic Area: Oncology Product Name: DSP-0337

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Boston Biomedical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger July 01, 2020

            Details:

            The merger of Tolero Pharmaceuticals and Boston Biomedical, and the formation of Sumitomo Dainippon Pharma Oncology aims to positively impact outcomes for patients with cancer by addressing unmet needs in oncology using its lead pipeline drug Napabucasin and other candidates.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Berubicin

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 30, 2020

            Details:

            CNS Pharmaceuticals has engaged Berry Consultants, a leading clinical statistical consulting group, to advise the Company ahead of its Phase 2 trial regarding its lead drug candidate Berubicin.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VIC-1911

            Therapeutic Area: Oncology Product Name: VIC-1911

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 29, 2020

            Details:

            Two Phase-1 clinical studies have been conducted in the US and Europe by Taiho. VITRAC obtained an exclusive and global development and commercialization rights for TAS-119, and its IND has been successfully transferred to VITRAC in the US with a new code name, VIC-1911.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AVA-001,Fludarabine,Cyclophosphamide

            Therapeutic Area: Oncology Product Name: AVA-001

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 29, 2020

            Details:

            Nine out of ten patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) have achieved complete remission (CR rate of 90%) within one month after the initiation of AVA-001 CAR T-cell therapy treatment.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Annamycin

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 25, 2020

            Details:

            A poster presentation entitled provided an overview of data demonstrating that uniquely high uptake and retention of Annamycin in the lungs results in consistently high in vivo activity against wide range of lung-localized tumors in mice.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CTX-471

            Therapeutic Area: Oncology Product Name: CTX-471

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Olivia Ventures

            Deal Size: $60.0 million Upfront Cash: Undisclosed

            Deal Type: Private Placement June 23, 2020

            Details:

            This transaction provides the resources necessary to advance our lead program, CTX-471, through clinical development, advance our second program, CTX-8371, to the clinic and continue to develop our pipeline of next-generation monoclonal and multispecific antibody therapeutics.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Zelenoleucel

            Therapeutic Area: Oncology Product Name: MT-401

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 23, 2020

            Details:

            United States Adopted Names (USAN) Council has approved “zelenoleucel” as the nonproprietary name for MT-401, a MultiTAA-specific T cell product candidate for the treatment of patients with AML following allogeneic stem cell transplant.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AMV564

            Therapeutic Area: Oncology Product Name: AMV564

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 23, 2020

            Details:

            AMV564 translational data for MDSC depletion, Treg control, favorable effector CD8 and CD4 Th1 polarization, along with a cytokine and chemokine milieu conducive to T cell trafficking and antigen presentation is consistent with relief of immune suppression.